DaVita Inc. (DVA)

The American Heart Association has introduced the Cardiovascular-Kidney-Metabolic (CKM) Health Initiative to increase awareness of the interconnected nature of heart disease, kidney disease, diabetes, and obesity. Nearly 90% of U.S. adults have at least one CKM risk factor, yet many cases remain undiagnosed. The initiative encourages regular screening and lifestyle modifications to prevent complications.

GlobeNewswire Inc.•Feature Impact

Mar 30

R1 Therapeutics, a new clinical-stage biopharmaceutical company, launched with an oversubscribed $77.5 million Series A financing co-led by Abingworth, DaVita Venture Group, and F-Prime. The company licensed exclusive global rights (outside Greater China) to AP306 from Alebund Pharmaceuticals, a first-in-class pan phosphate transporter inhibitor for treating hyperphosphatemia in chronic kidney disease patients on dialysis. R1 plans to advance Phase 2b clinical development of AP306, addressing a significant unmet need affecting over 40% of US dialysis patients.

GlobeNewswire Inc.•

Mar 17

Following Warren Buffett's retirement and Greg Abel's appointment as CEO of Berkshire Hathaway, the article highlights three Warren Buffett stocks with solid long-term potential: Chevron, benefiting from rising oil prices and operational improvements; Domino's Pizza, outperforming competitors with positive same-store sales growth and potential for higher valuation; and DaVita, showing signs of quiet recovery with strong Q4 results and promising 2026 guidance despite past struggles.

The Motley Fool•Thomas Niel

Mar 14

The article analyzes three Warren Buffett holdings: American Express is recommended as a buy despite a 20% pullback due to its strong position with affluent borrowers; Constellation Brands is suggested as a buying opportunity despite current weakness, as the beer industry is cyclical and the company is undergoing strategic improvements; DaVita is flagged as a stock to avoid due to deteriorating healthcare industry fundamentals and Berkshire's recent exit from the position.

The Motley Fool•James Brumley

Mar 8

Warren Buffett stepped down as Berkshire Hathaway CEO on December 31, 2025, after 60+ years. Q4 2025 results showed mixed performance with lower earnings due to $4.5B in impairments, but the company maintained a near-record $373.3B cash reserve. Buffett's final quarter moves included increasing positions in Chubb, Chevron, and The New York Times, while reducing stakes in Amazon, Bank of America, and DaVita. Over his tenure, Berkshire achieved 19.7% average annual gains versus the S&P 500's 10.1%.

Investing.com•Jordan Chussler

Mar 4

The article analyzes three Berkshire Hathaway holdings: DaVita and Kraft Heinz are recommended as strong buys due to positive earnings surprises and undervaluation, while UnitedHealth Group should be avoided despite recent dips, as it trades at a premium valuation with a deteriorating growth story amid lower Medicare Advantage payment increases.

The Motley Fool•Thomas Niel

Feb 9

Greg Abel, the new CEO of Berkshire Hathaway, has made his first reported stock sale by divesting 1.7 million shares of DaVita under a contractual agreement. The article also highlights Kraft Heinz as a potential candidate for sale, as Abel has registered to sell nearly all of Berkshire's 325 million shares and expressed disapproval of the company's planned split into two entities.

The Motley Fool•Adam Levy

Feb 6

DaVita Inc. (NYSE: DVA) surged 21.69% after reporting Q4 adjusted earnings of $3.40 per share, beating consensus of $3.16, and sales of $3.62 billion, up 5.8% YoY. The kidney care provider issued optimistic 2026 guidance with adjusted earnings of $13.60-$15.00 per share versus consensus of $12.65. The company also announced a $200 million minority investment in Elara Caring alongside Ares' Private Equity Group.

Benzinga•Vandana Singh

Feb 3

DaVita stock surged 20.3% on Tuesday following better-than-expected Q4 2024 earnings and improved full-year 2025 guidance. The dialysis treatment company reported adjusted EPS of $3.40 versus $2.51 year-over-year and projects 2025 EPS between $13.60-$15.00, significantly above the $10.78 achieved in 2024. Despite ongoing challenges from insurance reimbursement pressures and competition from home-based dialysis options, the stock appears undervalued at approximately 10x forward earnings.

The Motley Fool•James Brumley

Feb 3

A new American Heart Association initiative highlights the interconnected health of heart, kidney, and metabolic systems, revealing that 9 in 10 U.S. adults have at least one component of CKM syndrome, which increases risks of heart attack, stroke, and heart failure.

GlobeNewswire Inc.•Michael French

Nov 3, 2025